Category: Corporate NewsBy Rameda AdminAugust 13, 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Announces Price Increase Approvals for All Its Top ProductsNextNext post:Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketRelated PostsEarnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
